Filing identity and reporting period
Important mismatch: The supplied filing is JATT Acquisition Corp.’s Form 10-K, not a Zura Bio Ltd. filing. It covers JATT’s fiscal year ended December 31, 2021; because JATT was incorporated on March 10, 2021, the results are for the period from inception through year-end. This summary reflects the filing text provided.
Business context
JATT was a blank-check company formed to pursue a business combination, with a stated focus on life sciences businesses. At December 31, 2021, it had not identified or completed a combination, had no operations or operating revenue, and held its IPO funds primarily in trust.
Financial results and position
| Metric | Filing disclosure |
|---|---|
| Revenue | No operating revenue; none expected before a business combination. |
| Net income | $6.85 million for inception through December 31, 2021. Results included a $10.24 million non-cash gain from remeasuring warrant liabilities, partly offset by warrant issuance and offering-related expenses. |
| Operating expenses | $888,545, comprising $720,696 general and administrative expense and $167,849 related-party expense. |
| Cash flow | $1.10 million net cash used in operating activities; $141.21 million net cash provided by financing activities; $139.38 million deposited in trust. |
| Cash and liquidity | $729,223 unrestricted cash and approximately $880,000 working capital at year-end. Trust investments had a reported fair value of $139.40 million. |
| Debt and liabilities | No long-term debt or working-capital loans outstanding. Liabilities included $4.01 million deferred underwriting commissions and $6.07 million derivative warrant liabilities. |
| Equity and redemption | All 13.8 million Class A shares were subject to possible redemption and recorded outside permanent equity at $139.38 million, or $10.10 per share. Shareholders’ deficit was $9.18 million. |
Margins are not meaningful because the company had no operating revenue. The filing provides no comparable prior-year operating period.
Changes, outlook, and material matters
- The IPO and full over-allotment closed in July 2021, raising $138.0 million from units; the sponsor also purchased $5.91 million of private placement warrants. Approximately $139.38 million was placed in trust.
- JATT had until January 16, 2023 to complete a business combination; otherwise, it generally was required to redeem public shares and liquidate. Public warrants could expire worthless if no combination was completed.
- In January 2022, after year-end, forward purchase commitments were amended: planned purchases decreased from $75 million to $30 million; investors added a $15 million redemption backstop if redemptions exceeded 90%, and a proposed $30 million convertible-note bridge facility for the target. These were commitments described in the filing, not year-end cash or completed financing.
- Management and the auditor identified substantial doubt about JATT’s ability to continue as a going concern, citing limited working capital and the mandatory combination deadline. The financial statements include no liquidation-related adjustments.
- Management concluded disclosure controls were ineffective because of a material weakness in controls over accounting for complex financial instruments. Management said it performed additional analyses and was pursuing remediation; no assurance was given that remediation would succeed.
- Key risks include failure to find or complete a transaction, redemptions reducing available cash, potential need for additional financing, creditor claims against trust assets, conflicts of interest and limited management time. The sponsor’s trust indemnity may not be collectible; the filing says it was not funded by a reserve.
- The filing reports no material legal proceedings. It provides no operating guidance or revenue outlook.
Most important facts for investors to verify
- Confirm the issuer: the supplied document identifies JATT Acquisition Corp., not Zura Bio Ltd.
- Review the year-end cash available outside trust, the trust balance, redemption terms, and the January 16, 2023 combination deadline.
- Assess the going-concern warning and the company’s ability to fund search and transaction costs without committed working-capital loans.
- Verify the status and conditions of the amended forward purchase, redemption backstop, and convertible-note arrangements.
- Review the warrant-liability valuation and the material weakness in financial-instrument accounting controls, including subsequent remediation.
- Consider sponsor and management conflicts, creditor claims against trust assets, and the limitations of the sponsor’s indemnity.